Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
103Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $7.25M | $-17.41M | $-0.24 |
| 2024 | $566.0K | $-26.43M | $-0.37 |
| 2023 | $392.0K | $-52.34M | $-0.74 |
| 2022 | $1.50M | $-54.17M | $-0.77 |
| 2021 | $208.38M | $122.83M | $1.78 |
Social Signal Score
Earnings
Wed, Nov 11(in 3 months)
Consensus estimate $-0.12 per share
Typical surprise +18.8% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-0.08 vs $-0.12beat
- Tue, May 12$-0.12 vs $-0.12beat
- Wed, Mar 18$0.06 vs $-0.10beat
- Wed, Nov 12$-0.17 vs $-0.15miss
- Wed, Aug 13$-0.06 vs $-0.16beat
- Tue, May 13$-0.14 vs $-0.14beat
Estimates and results for OVID via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
OVIDhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (2)
- Newszacks.com·2d ago·Neutral
Ovid Therapeutics (OVID) Reports Q2 Loss, Beats Revenue Estimates Ovid Therapeutics (OVID) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.06 per share a year ago.
View source ↗ - Newsglobenewswire.com·2d ago·Neutral
Ovid Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today provided business updates including financial results for the second quarter ended June 30, 2026.
View source ↗